Felix Mueller
Clinical Researcher in Psychopharmacology
Data updated
Research Footprint
Felix Mueller appears in 13 tracked papers (2015–2025), most studied alongside LSD, MDMA and Psilocybin, across Healthy Volunteers, Neuroimaging & Brain Measures and Depressive Disorders.
Most-cited paper: Acute effects of lysergic acid diethylamide in healthy subjects (424 citations).
Frequent co-authors: Stefan Borgwardt, Matthias Liechti and Patrick Dolder.
Background & Research
Felix Mueller is a clinical researcher in psychopharmacology affiliated with the Department of Psychiatry at the University of Basel, Switzerland, and a recurrent collaborator in Swiss and international programmes investigating classical psychedelics. His work primarily focuses on the acute behavioural and neural effects of lysergic acid diethylamide (LSD) in healthy volunteers, using double-blind, placebo-controlled designs and multimodal neuroimaging to probe dose–response relationships, emotion processing, social cognition and the neural correlates of hallucinations.
Mueller's contributions include several influential experimental studies documenting dose-dependent subjective and physiological responses to LSD, acute impairment of fear recognition alongside increases in emotional empathy and sociality, and neuroimaging findings implicating altered thalamic resting-state connectivity and changes in network hub dynamics as mechanisms underlying LSD-induced perceptual and affective alterations. He has collaborated widely with investigators specialising in clinical trial methodology, psychopharmacology and brain imaging (including Liechti, Dolder, Schmid and others) and has been involved in work informing Swiss limited medical use frameworks and clinician education for psychedelic-assisted therapies.
Key Impact
Noted for leading double-blind, placebo-controlled human studies of LSD that combine psychometrics and neuroimaging to characterise dose-dependent subjective effects and acute changes in brain network connectivity.
Collaboration Network
23 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Felix Mueller is associated with.
University of Basel
academicThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
View stakeholder →Swiss Medical Society for Psycholytic Therapy
Non-ProfitThe Swiss Medical Society for Psycholytic Therapy, now presented on its site as SÄPT, is a Switzerland-based interdisciplinary medical society founded in 1986. It primarily serves German-speaking clinicians and related therapeutic professionals, including psychiatry, psychotherapy, neurology, palliative care, general medicine, psychology, and other therapeutic fields. Its core activities include professional exchange, training, and supporting medically supervised psychedelic-assisted therapy. SÄPT positions itself as a field-building organization for psychedelic-assisted therapy in Switzerland, with a focus on research support, quality standards, and professional education. Its website states that members have supported studies involving MDMA-assisted psychotherapy and LSD-assisted psychotherapy, and it currently lists ongoing or recent study and training announcements, including LSD studies for life-limiting illness, cluster headache, alcohol dependence, and older adults, plus an institutional PAT working group and treatment recommendations through IG PAT. It also provides patient-facing information on where psychedelic-assisted therapy may be available and on support options for difficult psychedelic experiences, which makes it a practical access and referral-adjacent stakeholder rather than a broad public advocacy group. Historically, SÄPT reports that five therapists received Swiss federal exception permits from 1988 to 1993 to conduct psychedelic-assisted therapy with MDMA and LSD in private practice, treating about 170 patients. Today it appears to operate mainly as a professional society that advances psycholytic therapy through education, research collaboration, ethical standards, and guidance for clinicians working within Switzerland’s restricted medical-use framework. Potential collaboration areas include clinical research, training, treatment standards, institutional implementation, and patient information pathways for researchers, clinicians, funders, policy groups, and patient communities.
View stakeholder →